Citadel Advisors
STRO icon

Citadel Advisors’s Sutro Biopharma STRO Stock Holding History

Citadel Advisors’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,780
Closed -$12.7K – 14050
2025
Q2 		$12.7K Buy
1,780
+1,700
+2,125% +$13.9K ﹤0.01% 12176
2025
Q1 		$520 Buy
+80
New +$1.26K ﹤0.01% 14252
2024
Q4 		– Sell
-210
Closed -$7.27K – 15357
2024
Q3 		$7.27K Buy
210
+190
+950% +$7.45K ﹤0.01% 13371
2024
Q2 		$586 Sell
20
-760
-97% -$30.1K ﹤0.01% 13958
2024
Q1 		$44.1K Buy
780
+610
+359% +$26.9K ﹤0.01% 12295
2023
Q4 		$7.29K Buy
170
+70
+70% +$2.22K ﹤0.01% 13295
2023
Q3 		$3.47K Sell
100
-210
-68% -$9.15K ﹤0.01% 13580
2023
Q2 		$14.4K Buy
310
+260
+520% +$12.9K ﹤0.01% 13003
2023
Q1 		$2.31K Sell
50
-350
-88% -$22.2K ﹤0.01% 14167
2022
Q4 		$32.3K Buy
+400
New +$27.8K ﹤0.01% 12646
2021
Q3 		– Sell
-1,300
Closed -$242K – 14617
2021
Q2 		$242K Sell
1,300
-350
-21% -$68.5K ﹤0.01% 11770
2021
Q1 		$376K Buy
+1,650
New +$392K ﹤0.01% 10332

Other funds holding STRO

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Citadel Advisors's STRO Position: Q2 2026 in Review

Citadel Advisors reduced its Sutro Biopharma (STRO) stake by 13% in Q2 2026, selling an estimated $486K and leaving 101,965 shares worth $3.39M. The position accounts for ﹤0.01% of the portfolio, ranked #5450.

Citadel Advisors first reported a position in STRO in Q3 2018 and has held it in 30 quarters since. The position peaked at $28.1M in Q4 2020. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

  • Citadel Advisors held 101,965 shares of Sutro Biopharma worth $3.39M as of Q2 2026.
  • Citadel Advisors sold 15,572 Sutro Biopharma shares in Q2 2026, an estimated $486K.
  • Sutro Biopharma made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #5450 holding.
  • Citadel Advisors first reported a position in Sutro Biopharma in Q3 2018 and has held it in 30 quarters since.
  • Citadel Advisors's Sutro Biopharma position peaked at $28.1M in Q4 2020.
  • 100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.